Sermorelin analogue - Akela Pharma

Drug Profile

Sermorelin analogue - Akela Pharma

Alternative Names: AKELA GHRH; AKL0707; LAB GHRH

Latest Information Update: 18 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Akela Pharma
  • Class Peptide hormones
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Nutrition disorders

Highest Development Phases

  • Discontinued Nutrition disorders

Most Recent Events

  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
  • 12 Mar 2013 Discontinued - Phase-II for Nutritional disorders in Europe (SC)
  • 15 Nov 2010 Sermorelin analogue - Akela Pharma is still available for licensing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top